About Emanuel Eguia, MD, MHA, MS

Dr. Emanuel Eguia, MD, MS, MHA, is an Assistant Professor in the Division of Surgical Oncology at Loma Linda University, specializing in the multidisciplinary treatment of hepatobiliary, pancreatic, and gastrointestinal malignancies. His clinical practice focuses on complex liver and pancreatic surgery, including minimally invasive and robotic approaches, with an emphasis on expanding access to advanced surgical and liver-directed therapies for patients with primary and metastatic hepatobiliary cancers.

Dr. Eguia earned his Bachelor of Science in Cell, Molecular, and Developmental Biology and Master of Healthcare Administration from the University of Washington, followed by his medical degree from the University of Washington School of Medicine. He completed his general surgery residency at Loyola University Chicago, where he also earned a Master of Science in Clinical Research Methods and Epidemiology and completed a two-year NIH T32 Health Services Research Fellowship. He subsequently completed fellowship training in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Eguia’s clinical and academic interests center on advancing the care of patients with liver, pancreatic, biliary, and gastrointestinal cancers through multidisciplinary treatment strategies, innovative surgical techniques, and evidence-based program development. He has particular expertise and interest in minimally invasive and robotic hepatopancreatobiliary surgery, colorectal liver metastases, and advanced liver-directed therapies.

At Loma Linda University Health, Dr. Eguia helped develop and establish the Hepatic Artery Infusion (HAI) Pump Program, expanding access to regional liver-directed therapy for patients with advanced hepatic malignancies. He has a particular clinical interest in the use of HAI therapy for patients with colorectal liver metastases and intrahepatic cholangiocarcinoma, including multidisciplinary strategies to improve disease control, increase opportunities for surgical resection, and expand treatment options for patients with otherwise unresectable liver-dominant disease.

His research program focuses on improving cancer outcomes and access to high-quality surgical care through artificial intelligence, machine learning, health services research, and geospatial methods. His work integrates clinical, socioeconomic, and geographic data to develop predictive and clinical decision-support tools to identify disparities, improve patient selection, and reduce barriers to potentially curative cancer treatment, particularly in underserved and resource-limited communities.

Through his clinical practice, research, and program-building efforts, Dr. Eguia is committed to developing a comprehensive, multidisciplinary HPB oncology program that combines complex liver and pancreatic surgery, minimally invasive and robotic techniques, advanced liver-directed therapies such as HAI, and patient-centered multidisciplinary cancer care.